YIL092W Antibody

What is YIL092W protein and what are its characteristics in Saccharomyces cerevisiae?

YIL092W is a protein found in Saccharomyces cerevisiae (strain ATCC 204508 / S288c), commonly known as Baker's yeast. This protein is encoded by the YIL092W gene, and antibodies against this protein are typically developed using recombinant protein as the immunogen . When designing experiments involving this protein, researchers should consider:

• The subcellular localization of YIL092W in yeast cells

• Its molecular weight for appropriate gel analysis

• Expression patterns under various growth conditions

• Potential interactions with other yeast proteins

Understanding these basic characteristics is essential for interpreting experimental results and designing appropriate controls when using YIL092W antibodies.

What applications is the YIL092W antibody suitable for in yeast research?

Based on available characterization data, YIL092W antibodies have been tested and validated for specific applications including:

• Enzyme-Linked Immunosorbent Assay (ELISA)

• Western Blotting (WB)

When planning experiments, researchers should ensure that the antibody has been specifically validated for their intended application. Not all antibodies perform equally well across different techniques, and application-specific validation is crucial for reliable results. According to reproducibility experts, approximately 50% of commercial antibodies fail to meet basic standards for characterization, which highlights the importance of application-specific validation .

What are the recommended storage and handling conditions for YIL092W antibody?

To maintain antibody integrity and experimental reproducibility, YIL092W antibody should be stored according to these guidelines:

• Upon receipt, store at -20°C or -80°C

• Avoid repeated freeze-thaw cycles that can degrade antibody quality

• The antibody is typically supplied in liquid form with a storage buffer containing preservatives (e.g., 0.03% Proclin 300) and stabilizers (e.g., 50% Glycerol, 0.01M PBS, pH 7.4)

What controls should be included when using YIL092W antibody in experiments?

Including appropriate controls is essential for rigorous research with antibodies. For YIL092W antibody, consider the following controls:

• Positive control: Lysate from wild-type S. cerevisiae known to express YIL092W

• Negative control: One of the following:

  • Lysate from a YIL092W knockout strain

  • Pre-immune serum for the same dilution as the primary antibody

  • Primary antibody omission control

The importance of knockout controls cannot be overstated. Research has shown that using knockout cell lines as controls is one of the most reliable methods for antibody validation, and initiatives like YCharOS collaborate with knockout cell line producers to improve antibody characterization .

How can I validate the specificity of YIL092W antibody for my experimental conditions?

Antibody validation is critical for ensuring experimental rigor. For YIL092W antibody, consider these validation methods:

• Knockout validation: Use a YIL092W knockout strain as a negative control

• Recombinant protein competition: Pre-incubate the antibody with purified YIL092W protein before the experiment

• Multiple antibody verification: Use another antibody against a different epitope of YIL092W

• Mass spectrometry correlation: Confirm antibody targets by mass spectrometry analysis

According to recent research, inadequate antibody characterization costs the scientific community between $0.4-1.8 billion per year in the United States alone due to non-reproducible results . Proper validation saves resources and improves research quality.

What factors affect YIL092W antibody performance across different experimental conditions?

The performance of YIL092W antibody can be influenced by multiple factors:

Advanced research requires systematic optimization of these conditions to maximize signal-to-noise ratio and ensure reproducible results. This is particularly important as the AI-driven antibody design platforms described in recent research emphasize the critical role of experimental conditions in antibody performance .

How can I troubleshoot false positives or negatives when using YIL092W antibody?

When encountering unexpected results with YIL092W antibody, consider this systematic troubleshooting approach:

For false positives:

• Increase antibody dilution to reduce non-specific binding

• Modify washing steps (increase duration/stringency)

• Change blocking reagents to reduce background

• Perform peptide competition assays to confirm specificity

• Verify with a knockout strain as the gold standard negative control

For false negatives:

• Confirm target protein expression under your conditions

• Optimize protein extraction to ensure the epitope is accessible

• Try different antibody concentrations

• Modify incubation conditions (time, temperature)

• Consider epitope masking due to protein interactions or modifications

Current research emphasizes that even FDA-authorized antibodies can lose efficacy against mutated targets, highlighting the importance of continuous validation and troubleshooting .

How can YIL092W antibody be integrated with other techniques for comprehensive protein analysis?

For advanced protein characterization, YIL092W antibody can be integrated with multiple techniques:

• Immunoprecipitation followed by mass spectrometry (IP-MS):

  • Enables identification of interaction partners

  • Provides confirmation of antibody specificity

  • Allows characterization of post-translational modifications

• Chromatin Immunoprecipitation (ChIP) if relevant:

  • Identifies DNA binding sites if YIL092W has DNA-binding properties

  • Requires additional validation specific to ChIP protocols

• Proximity Labeling with antibody detection:

  • BioID or APEX2 tagging combined with antibody detection

  • Provides spatial context for protein interactions

• Super-resolution microscopy:

  • Combines immunofluorescence with advanced imaging

  • Requires specific validation for fluorescence applications

Recent advances in machine learning approaches for antibody characterization, as seen in the GUIDE platform, can help predict how antibodies will perform in these integrated techniques .

What considerations are important when using YIL092W antibody across different yeast strains or genetic backgrounds?

When extending research to different yeast strains, researchers should consider:

• Sequence conservation: Verify YIL092W sequence similarity across strains

• Expression levels: Different strains may have varying baseline expression

• Post-translational modifications: These may differ between strains

• Epitope accessibility: Protein folding or interactions may vary

A methodological approach requires:

• Validation in each new strain with appropriate controls

• Potential adjustment of antibody concentration for different strains

• Consideration of strain-specific interfering factors

• Documentation of optimization parameters for reproducibility

This is particularly important as research initiatives like the Antibody Society emphasize that antibody performance can vary significantly across different genetic backgrounds .

What are the best practices for quantitative analysis of YIL092W protein expression using this antibody?

For accurate quantification of YIL092W protein:

• Establish a standard curve:

  • Use purified recombinant YIL092W protein at known concentrations

  • Process standards identically to samples

• Ensure linear detection range:

  • Validate that signal intensity correlates linearly with protein concentration

  • Determine upper and lower detection limits

• Normalize appropriately:

  • Use consistent loading controls (e.g., total protein staining)

  • Consider housekeeping proteins specific to yeast (e.g., actin, TDH3)

• Image analysis best practices:

  • Use software that avoids saturation

  • Apply consistent analysis parameters across experiments

  • Perform replicate measurements to establish variability

The importance of quantitative validation is highlighted by initiatives like YCharOS, which works with antibody manufacturers to characterize antibodies and identify high-performing products for research use .

How should experimental results using YIL092W antibody be reported in publications?

To enhance reproducibility, publications using YIL092W antibody should include:

• Complete antibody information:

  • Manufacturer and catalog number

  • Lot number (as performance can vary between lots)

  • Clonality (polyclonal or monoclonal)

  • Host species and immunogen details

• Detailed methods:

  • Antibody dilution and incubation conditions

  • Buffer compositions

  • Complete protocol including washing steps

  • Image acquisition parameters

• Validation evidence:

  • Description of controls used

  • Supporting data demonstrating specificity

  • Mention of any optimization required

Using Research Resource Identifiers (RRIDs) for antibodies in publications helps track reagent use and facilitates reproducibility efforts across the scientific community .

What are the ethical considerations for developing and using YIL092W antibodies?

When working with antibodies derived from animals, researchers should consider:

• Source ethics:

  • Ensure antibodies were produced following animal welfare guidelines

  • Consider alternatives to animal-derived antibodies when possible

• Resource sharing:

  • Share detailed characterization data

  • Consider depositing antibodies in repositories

  • Contribute to community validation efforts

• Responsibility to research community:

  • Report both positive and negative findings regarding antibody performance

  • Avoid perpetuating use of poorly characterized antibodies

These considerations align with recent calls for improving the integrity and reproducibility of research using antibodies, which emphasize that addressing antibody reliability is both a technical and ethical challenge .

How might emerging antibody technologies improve YIL092W protein research?

Emerging technologies that could enhance YIL092W antibody research include:

• Recombinant antibody development:

  • Creating renewable, sequence-defined antibodies against YIL092W

  • Eliminating batch-to-batch variability of polyclonal antibodies

  • Enabling precise epitope targeting

• AI-driven antibody design:

  • Using computational approaches to predict optimal antibody sequences

  • Employing machine learning to enhance specificity, as demonstrated by the GUIDE platform

  • Reducing development time and improving performance

• Nanobodies and alternative binding proteins:

  • Developing smaller binding proteins with improved penetration

  • Creating fusion proteins for novel applications

• Multiplexed detection systems:

  • Enabling simultaneous detection of YIL092W and other yeast proteins

  • Providing contextual information about protein networks

These approaches align with current trends in antibody technology development that prioritize reproducibility and defined reagents .

How can researchers contribute to improving YIL092W antibody characterization?

Individual researchers can contribute to community knowledge by:

• Systematic characterization:

  • Testing antibody performance across multiple applications

  • Documenting optimization parameters

  • Using knockout controls for definitive validation

• Data sharing:

  • Publishing detailed methods and validation data

  • Contributing to antibody validation initiatives

  • Reporting issues with commercially available antibodies

• Collaborative approaches:

  • Participating in community-based characterization efforts

  • Engaging with initiatives like YCharOS or scientific society working groups

  • Sharing resources such as knockout strains

This collaborative approach is essential, as the "Only Good Antibodies" initiative emphasizes that improving antibody research quality requires engagement from multiple stakeholders .